Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress

Archives of Medical Research

Volumn 45, Issue 7, 2014, Pages 589-595

  Farhangi, Mahdieh Abbasalizad ^a   Alipour, Beytollah ^a   Jafarvand, Elnaz ^a   Khoshbaten, Manouchehr ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coenzyme Q10; Insulin resistance; Nonalcoholic fatty liver disease (NAFLD); Oxidative stress

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHEMERIN; GLUCOSE; MALONALDEHYDE; PENTRAXIN 3; PLACEBO; UBIDECARENONE; VASPIN; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMERIN, HUMAN; CHEMOKINE; GLUCOSE BLOOD LEVEL; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; SERUM AMYLOID P; UBIQUINONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ASSAY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; YOUNG ADULT;

ADIPOKINES; ADULT; ALANINE TRANSAMINASE; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHEMOKINES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SERPINS; SERUM AMYLOID P-COMPONENT; UBIQUINONE; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84915803580     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.11.001     Document Type: Article

References (45)

1. Erickson S.K. Nonalcoholic fatty liver disease. J Lipid Res 2009, 50(suppl):412-416.
2. Buechler C. Chemerin in non-alcoholic fatty liver disease? Up or down?. Endocrinol Metab Syndr 2013, 2:1-3.
3. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(suppl):99-112.
4. Browning J.D., Szczepaniak L.S., Dobbins R. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
5. Adams L.A., Lymp J.F., St Sauver J. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
6. Chitturi S., Wong V.W., Farrell G., et al. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011, 26(suppl):163-172.
7. Jarrar M.H., Baranova A., Collantes R., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
8. Krautbauer S., Wanninger J., Eisinger K., et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol 2013, 95:199-205.
9. Yoshimura T., Oppenheim J.J. Chemerin reveals its chimeric nature. J Exp Med 2008, 205:2187-2190.
10. Roh S.G., Song S.H., Choi K.C., et al. Chemerin: a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007, 362:1013-1018.
11. Takahashi M., Takahashi Y., Takahashi K., et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008, 582:573-578.
12. Docke S., Lock J.F., Birkenfeld A.L., et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol 2013, 169:547-557.
13. Aktas B., Yilmaz Y., Eren F., et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism 2011, 60:544-549.
14. Yilmaz Y., Kurt R., Gurdal A., et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2008, 217:125-129.
15. Kukla M., Zwirska-Korczala K., Hartleb M., et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010, 45:235-242.
16. Crane F.L. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001, 20:591-598.
17. Sohet F.M., Neyrinck A.M., Pachikian B.D., et al. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol 2009, 78:1391-1400.
18. Carmona M.C., Lefebvre P., Lefebvre B., et al. Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes 2009, 33:204-211.
19. Schmelzer C., Lindner I., Rimbach G., et al. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008, 32:179-183.
20. El-Hamid M.A., El-Halim M.S., Karima I., et al. Role of coenzyme Q10, metformin and rosiglitazone in treatment of experimental nonalcoholic steatohepatitis in rats. Tanta Med Sc J 2008, 3:15-29.
21. Bravo E., Palleschi S., Rossi B., et al. Coenzyme Q metabolism is disturbed in high fat diet-induced nonalcoholic fatty liver disease in rats. Int J Mol Sci 2012, 13:1644-1657.
22. Ikematsu H., Nakamura K., Harashima S., et al. Safety assessment of coenzyme Q10 in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol 2006, 44:212-218.
23. Hathcock J.N., Shao A. Risk assessment for coenzyme Q10. Regul Toxicol Pharmacol 2006, 45:282-288.
24. Hidaka T, Fujii K, Funahashi I, etal. Overview of safety assessment ofcoenzyme Q10: animal and human data. The 5th Conference of the International CoQ10 Association, 2007 Nov 9-12; Kobe, Japan.
25. World Health Organization (WHO). Waist circumference and waist-hip ratio. Report of a WHO expert consultation, Geneva: 8-11 December2008.
26. International Physical Activity Questionnaire (IPAQ) guidelines for data processing and analysis of the international physical activity questionnaire. November 2005. Available from: . http://www.ipaq.ki.se/scoring.pdf.
27. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
28. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
29. Viner R.M., Segal T.Y., Lichtarowicz-Krynska E., et al. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005, 90:10-14.
30. Mihara M., Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978, 86:271-278.
31. Jimenez-Santos M.A., Juarez-Rojop I.E., Tovilla-Zarate C.A., et al. Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. Lipids Health Dis 2014, 13:22-32.
32. Hodgson J.M., Watts G.F., Playford D.A., et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56:1137-1142.
33. Bour S., Carmona M.C., Galinier A., et al. Coenzyme Q as an antiadipogenic factor. Antioxid Redox Signal 2011, 14:403-413.
34. Esfahani S.A., Esmaeilzadeh E., Bagheri F., et al. The effect of co-enzyme Q10 on acute liver damage in rats: a biochemical and pathological study. Hepat Mon 2013, 13:e13658.
35. Lee B.J., Huang Y.C., Chen S.J., et al. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012, 28:250-255.
36. Leelarungrayub D., Sawattikanon N., Klaphajone J., et al. Coenzyme Q10 supplementation decreases oxidative stress and improves physical performance in young swimmers: a pilot study. Open Sports Med J 2010, 4:1-8.
37. Rostami A., Jafari A. Effect of short-term coenzyme Q10 supplementation on oxidative stress index and total antioxidant capacity of serum in inactive men. Med J Tabriz Univ Med Sci 2012, 34:46-51.
38. Cooke M., Iosia M., Buford T., et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr 2008, 5:1-14.
39. 10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011, 14:386-390.
40. Mohammadshahi M., Farsi F., Alavi-Nejad P., et al. The coenzyme Q10 supplementation effects on lipid profile, fasting blood sugar, blood pressure and oxidative stress status among non-alcoholic fatty liver disease patients: a randomized, placebo-controlled, pilot study. J Gastroentrol Hepatic Res 2014, 3:1103-1108.
41. Wada J. Vaspin: a new serpin with insulin sensitizing effects. Expert Opin Investig Drugs 2008, 17:327-333.
42. Yin Y., Xu-hong H., Xiao-ping P., et al. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J 2009, 122:2530-2533.
43. Tan B.K., Heutling D., Chen J., et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008, 57:1501-1507.
44. Peri G., Introna M., Corradi D., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
45. Zanetti M., Bosutti A., Ferreira C., et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009, 9:243-248.